Ipsen (IPN) Investor Presentation summary

Vision and strategy

• Aims to be a leading global mid-sized biopharmaceutical company focused on transformative medicines in oncology, rare disease, and neuroscience.

• Strategy centers on maximizing the potential of innovative medicines, building a high-value sustainable pipeline, and fostering a collaborative culture.

• Focused on specialty care, with a balanced and diversified portfolio across three therapy areas.

Product portfolio and launches

• Nine major medicines span oncology, rare disease, and neuroscience, including Dysport, Cabometyx, Onivyde, Somatuline, Decapeptyl, Bylvay, Sohonos, Tazverik, and IQIRVO.

• Four new medicines or indications launched or underway: Onivyde (1L mPDAC), Bylvay (ALGS), IQIRVO (2L PBC), and Sohonos (FOP).

• Portfolio diversification increased from one medicine with sales ≥€500m in 2020 to four in 2023, with seven expected by 2027+.

Financial performance and outlook

• 2023 total sales show a balanced split: oncology (75%), neuroscience (21%), and rare disease (4%).

• Regional sales: Europe (40%), North America (33%), Rest of World (27%), with growth opportunities in all regions.

• 2027 mid-term outlook targets ≥7% CAGR in total sales and core operating margin ≥32% of sales, driven by new launches and pipeline expansion.